Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 11/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.42 |
| ▸ | GSTK1 | Q9Y2Q3 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4331999 | 0.86 | FOLH1 (0.62) | FOLH1 | |
| SCHEMBL11777462 | 0.84 | FOLH1 (0.55) | FOLH1LMNASLC22A6ENPEPGSTK1 | |
| SCHEMBL11238060 | 0.83 | FOLH1 (0.65) | FOLH1LMNASLC22A6ENPEPGSTK1 | |
| SCHEMBL5692955 | 0.81 | FOLH1 (0.67) | FOLH1LMNASLC22A6GSTK1TSHR | |
| SCHEMBL500865 | 0.81 | FOLH1 (0.73) | FOLH1 | |
| SCHEMBL9538314 | 0.81 | FOLH1 (0.63) | FOLH1LMNASLC22A6ENPEPGSTK1 | |
| SCHEMBL480069 | 0.79 | CHRM1 (0.42) | FOLH1 | |
| SCHEMBL2483229 | 0.79 | FOLH1 (0.74) | FOLH1LMNASLC22A6ENPEPTSHR | |
| SCHEMBL8075329 | 0.78 | FOLH1 (0.55) | FOLH1LMNAENPEPGSTK1TSHR | |
| SCHEMBL7863633 | 0.78 | FOLH1 (0.55) | FOLH1LMNAENPEPGSTK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759749-B2 | Therapeutic agent for diabetes | JCR PHARMACEUTICALS CO., LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| EP-3508474-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR Pharmaceuticals Co., Ltd. (JP) | 2019-07-10 | — | — | EP | disclosed |
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR PHARMACEUTICALS CO., LTD. (JP) | 2019-07-04 | — | — | US | disclosed |
| US-10256169-B2 | Semiconductor device | FUJI ELECTRIC CO., LTD. (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20170278771-A1 | SEMICONDUCTOR DEVICE | FUJI ELECTRIC CO., LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
| CN-1276035-C | Water-color ink | MITSUI CHEMICALS INC (JP) | 2006-09-20 | — | — | CN | disclosed |
| CN-1558934-A | Water-color ink | 三井化学株式会社 | 2004-12-29 | — | — | CN | disclosed |
| US-20040231558-A1 | Has a clear hue, high light fastness and high moisture resistance | MITSUI CHEMICALS, INC. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1441013-A1 | WATERCOLOR INK | Mitsui Chemicals, Inc. (JP) | 2004-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | GPR119, IAPP, DPP4 | FOLH1 1309/4885LMNA 4657/4885SLC22A6 1171/4885 |
| US-10759749-B2 | Therapeutic agent for diabetes | GPR119, IAPP, DPP4 | FOLH1 1428/4885LMNA 4517/4885SLC22A6 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.